Minister of Investment Receives Minister Delegate for Foreign Trade and Economic Attractiveness of France    Ministry of Islamic Affairs Stresses Necessity of Wearing Mask and Social Distancing in Mosques    AFC President: The Global Event Formula 1 Reflects the Ambitious Vision of HRH the Crown Prince    UAE condemns terrorist Houthi militia attempt to target Saudi Arabia with drones    India reports 8,895 new infections of coronavirus    Germany Records 27,836 New COVID-19 Cases    Trafficking is a crime that can happen in front of our eyes: UNODC    Veteran US Republican leader Bob Dole dies aged 98    US Congressman condemned for Christmas guns photo    Nazaha arrests 250 government staff on charges of corruption    5-day Jeddah international motor show starts Today at 6 PM    MoH: Wearing mask is mandatory in crowded open areas    Lewis Hamilton wins thrilling Saudi Arabian Grand Prix    Crown Prince attends inaugural Saudi Arabian Grand Prix    Custodian of the Two Holy Mosques Sends Written Message to Sultan of Oman    Saudi Stock Exchange Main Index Ends Trading Higher at 11,142 Points    Jeddah international motor show to kick off Monday    King, Crown Prince congratulate Finland president on Independence Day    RSNF launches last warship of Sarawat Corvette Project in Spain    Saudia, CFM sign SR32 billion LEAP-1A engines purchase agreement    Deputy Governor of Hail: Hail International Rally is a practical translation of the wise leadership's support    Hail International Rally to Kick off Tomorrow    SAMI, Airbus to Form Joint Venture for Military Aviation MRO and Services    Death Toll Rises to 13 after Indonesia's Semeru Volcano Erupts    Saudi-French MoU signed, signalling new era of cultural collaboration    Crown Prince, Macron, and Mikati hold joint phone talks Saudi Arabia, France agree with Lebanon for joint work to boost its reforms, stability    Saudi Aramco, French Companies Sign Agreements    MODON Takes Part in Inlet Europe 2021 Summit in Italy    Asian Handball Federation Representatives Conclude Inspecting Sports Facilities in Eastern Region    Formula 1 STC Saudi Arabian Grand Prix 2021 Official Race to Kick off Tomorrow in Jeddah    Hamilton sets pace in free trials in Formula 1 STC Saudi Arabian Grand Prix    Invest in Saudi Arabia initiative announces partnership with F1 Saudi Grand Prix    Red Sea Immersive to provide enthralling experience: Liz Rosenthal    Duchess of Sussex wins latest court battle with Mail on Sunday publisher    Trolls join UN campaign for healthier eating, sustainable living    BIENALSUR Exhibition arrives in Jeddah at historic site of Qasr Khuzam    Saudi Hind Al-Showaier Elected Regional Director of World Federation of the Deaf    Saudi Film Commission launch its strategy to develop film and cinema sector    Bollywood superstar Salman Khan to dazzle Riyadh Season on Dec. 10    First Full International Marathon in Saudi Arabia to be Held in March 2022    Winter Wonderland Circus Amazes Audience with Thrilling Acrobatic Shows    Bollywood star's 'India got freedom in 2014' remark stirs controversy    23 Saudi women obtain favorable verdicts in 'adhl' lawsuits    Bride's fingerprint not required in revised e-marriage contract    Pilgrims Perform Dhuhr and Asr Prayers at Arafat Holy Site    Council of Senior Scholars: Muslim Brothers' Group Don't Represent Method of Islam, rather only Follows its Partisan Objectives, Violating our Graceful Religion    Eid Al-Adha Prayer Performed at the Grand Holy Mosque    Pilgrims Perform Dhuhr and Asr Prayers in Arafat Holy Site    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



Sanofi, GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
Published in The Saudi Gazette on 16 - 04 - 2020

Sanofi and GSK Thursday announce that they have signed a letter of intent to enter into a collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.
Sanofi will contribute its S-protein COVID-19 antigen, which is based on recombinant DNA technology. This technology has produced an exact genetic match to proteins found on the surface of the virus, and the DNA sequence encoding this antigen has been combined into the DNA of the baculovirus expression platform, the basis of Sanofi's licensed recombinant influenza product in the US.
GSK will contribute its proven pandemic adjuvant technology to the collaboration. The use of an adjuvant can be of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people.
Paul Hudson, CEO Sanofi, said: "As the world faces this unprecedented global health crisis, it is clear that no one company can go it alone. That is why Sanofi is continuing to complement its expertise and resources with our peers, such as GSK, with the goal to create and supply sufficient quantities of vaccines that will help stop this virus."
Emma Walmsley, CEO GSK, said: "This collaboration brings two of the world's largest vaccines companies together. By combining our science and our technologies, we believe we can help accelerate the global effort to develop a vaccine to protect as many people as possible from COVID-19."
The combination of a protein-based antigen together with an adjuvant, is well-established and used in a number of vaccines available today. An adjuvant is added to some vaccines to enhance the immune response, and has been shown to create a stronger and longer lasting immunity against infections than the vaccine alone. It can also improve the likelihood of delivering an effective vaccine that can be manufactured at scale.
The companies plan to initiate phase I clinical trials in the second half of 2020 and, if successful and subject to regulatory considerations, aim to complete the development required for availability by the second half of 2021.
As previously announced by Sanofi, development of the recombinant-based COVID-19 vaccine candidate is being supported through funding and a collaboration with the Biomedical Advanced Research and Development Authority (BARDA), in the US. The companies plan to discuss funding support with other governments and global institutions prioritizing global access.
BARDA Director, Rick A. Bright, Ph.D., said: "Strategic alliances among vaccine industry leaders are essential to make a coronavirus vaccine available as soon as possible. Development of the adjuvanted recombinant-based COVID-19 vaccine candidate holds the potential to lower the vaccine dose to provide vaccine to a greater number of people to end this pandemic, and help the world become better prepared or even prevent future coronavirus outbreaks."
The companies have set up a Joint Collaboration Task Force, co-chaired by David Loew, global head of vaccines, Sanofi and Roger Connor, president vaccines, GSK. The taskforce will seek to mobilize resources from both companies to look for every opportunity to accelerate the development of the candidate vaccine.
Considering the extraordinary humanitarian and financial challenge of the pandemic, both companies believe that global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public and through mechanisms that offer fair access for people in all countries.
This new collaboration marks a significant milestone in Sanofi's and GSK's ongoing contributions to help fight COVID-19. The companies have entered into a Material Transfer Agreement to enable them to start working together immediately. Definitive terms of the collaboration are expected to be finalized over the next few weeks. — SG


Clic here to read the story from its source.